Evidence map›Paper›PMID 26348977›Full record

ArticleScientific reports2015

Epigenetic Regulation of Antibody Responses by the Histone H2A Deubiquitinase MYSM1.

Xiao-Xia Jiang, YuChia Chou, Lindsey Jones, Tao Wang, Suzi Sanchez, Xue F Huang, Lei Zhang, Changyong Wang, Si-Yi Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. MYSM1 Is Essential for Maintaining Hematopoietic Stem Cell (HSC) Quiescence and Survival.Medical science monitor : international medical journal of experimental and clinical research · 2018
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xiao-Xia JiangDepartment of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center Keck School of Medicine, University of Southern California, Los Angeles, California, 90033, USA.
YuChia ChouDepartment of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center Keck School of Medicine, University of Southern California, Los Angeles, California, 90033, USA.
Lindsey JonesDepartment of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center Keck School of Medicine, University of Southern California, Los Angeles, California, 90033, USA.
Tao WangDepartment of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center Keck School of Medicine, University of Southern California, Los Angeles, California, 90033, USA.
Suzi SanchezDepartment of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center Keck School of Medicine, University of Southern California, Los Angeles, California, 90033, USA.
Xue F HuangDepartment of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center Keck School of Medicine, University of Southern California, Los Angeles, California, 90033, USA.
Lei ZhangDepartment of Advanced Interdisciplinary Studies, Institute of Basic Medical Sciences, Beijing, 100850, China.
Changyong WangDepartment of Advanced Interdisciplinary Studies, Institute of Basic Medical Sciences, Beijing, 100850, China.
Si-Yi ChenDepartment of Molecular Microbiology and Immunology, Norris Comprehensive Cancer Center Keck School of Medicine, University of Southern California, Los Angeles, California, 90033, USA.
University of Southern California · USInstitute of Basic Medical Sciences of the Chinese Academy of Medical Sciences

Funding

Overcoming Immune Suppression to Enhance Tumor Vaccine EfficacyR01CA090427 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHEN, SI-YI · 2002 to 2013
$3.1M
Developing novel adjuvants for HIV vaccinationR01AI084811 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHEN, SI-YI · 2009 to 2013
$2.2M
HIV vaccination via inhibition of cytokine signaling inhibitorsR01AI068472 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHEN, SI-YI · 2006 to 2010
$1.7M
A Novel Oncolytic HSP Vaccine for Systemic Tumor TherapyR01CA100841 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI HUANG, XUE F · 2006 to 2010
$1.1M
Tumor Vaccination: Modulation of Inhibitory Signaling in Antigen-presenting cellsR01CA116677 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHEN, SI-YI · 2006 to 2009
$988k
NCI NIH HHS CA100841NCI NIH HHS CA116677NCI NIH HHS R01 CA090427NCI NIH HHS R01CA090427NCI NIH HHS R01 CA100841NCI NIH HHS R01 CA116677NIAID NIH HHS AI068472NIAID NIH HHS AI08185NIAID NIH HHS AI084811NIAID NIH HHS R01 AI068472NIAID NIH HHS R01 AI084811
6 · The paper itself

Abstract

B cell-mediated antibody response plays critical roles in protective immunity, as well as in the pathogenesis of allergic and autoimmune diseases. Epigenetic histone and DNA modifications regulate gene transcription and immunity; however, so far, little is known about the role of epigenetic regulation in antibody responses. In this study, we found that mice deficient in the histone H2A deubiquitinase MYSM1, despite their severe defect in B cell development, exhibit an enhanced antibody response against both T cell-dependent and independent antigens. We revealed that MYSM1 intrinsically represses plasma cell differentiation and antibody production. Mechanistic studies demonstrated that MYSM1 is a transcriptional activator of Pax5, the repressors of plasma cell differentiation, by facilitating key transcriptional factor recruitment and coordinating histone modifications at the Pax5 loci. Hence, this study uncovers a critical role for MYSM1 in epigenetically repressing plasma cell differentiation and antibody production, in addition to its opposing, active role in B cell development. Importantly, this study further provides a new target and strategy to modulate antibody production and responses with profound therapeutic implications.

Indexed as

Epigenesis, GeneticGene Expression RegulationAnimalsAntibody FormationBasic-Leucine Zipper Transcription FactorsB-LymphocytesCell DifferentiationDNA-Binding ProteinsEndopeptidasesImmunoglobulinsImmunologic MemoryLymphocyte ActivationMiceMice, KnockoutPAX5 Transcription FactorPlasma CellsBach2 protein, mouseBasic-Leucine Zipper Transcription FactorsDNA-Binding ProteinsEndopeptidasesImmunoglobulinsMYSM1 protein, mousePax5 protein, mousePAX5 Transcription FactorPositive Regulatory Domain I-Binding Factor 1Prdm1 protein, mouseProto-Oncogene ProteinsProto-Oncogene Protein Spi-1Regulatory Factor X Transcription FactorsTrans-ActivatorsTranscription FactorsUbiquitin-Specific Proteases

Identifiers

PMID26348977
PMCPMC4562257
OpenAlexW2416323706

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.